1. INTRODUCTION {#sec1}
===============

Advanced age is an important risk factor of dementia, which affects about 10% of people aged 65, with the rate reaching about 40% in 90-year olds \[[@r1]\]. According to the World Health Organization, around 50 million people worldwide suffer from dementia, and there are nearly 10 million new cases every year \[[@r2]\]. In the United States, every 65 seconds, an individual develops Alzheimer's disease \[[@r1]\]. In view of the predicted lifespan elongation, neurodegenerative diseases will soon become focal points in the health and social care systems of modern societies \[[@r3]\].

Dementia is a term used to describe different brain conditions with common characteristics of the loss of intellectual and cognitive functions \[[@r4], [@r5]\]. It refers to a clinical syndrome characterized by a progressive cognitive decline that interferes with the ability to function independently \[[@r6], [@r7]\]. Symptoms of dementia are gradual, persistent and progressive; individuals experience changes in cognition, function and

behavior \[[@r8]\]. The clinical presentation of the syndrome varies greatly among individuals causing impairments such as memory loss, communication and language impairments, agnosia, apraxia and impaired executive function \[[@r9]\].

1.1. Dementia and Mild Cognitive Impairment {#sec1.1}
-------------------------------------------

The process of neurodegeneration, resulting from the production of degenerated proteins, is at the heart of many neurological conditions and diseases \[[@r10]\]. Due to the fact that neurons cannot reproduce, the process is irreversible. The most prevalent neurodegenerative disease is Alzheimer's Disease (AD), comprising 60% to 80% of cases \[[@r11]\]. Dementia with Lewy Bodies (DLB) accounts for 15% of all dementias \[[@r12]\], and Frontotemporal Dementia (FTD) for 8 - 10% of the cases \[[@r13]\]. Vascular Dementia (VaD), the second most prevalent form (20%) \[[@r14]\] results from cerebrovascular disease, therefore a causal/temporal relationship between a vascular event and cognitive impairment has to be demonstrated \[[@r15]\]. The vascular disease frequently coexists with a cognitive decline in aging individuals, and shares many risk factors with dementia that are considered to be of the "Alzheimer-type," and are observed more frequently than that expected in postmortem material from individuals manifesting disease stigmata such as abundant plaques and tangles \[[@r16], [@r17]\]. Other dementias, caused by potentially reversible factors \[[@r18]\] may occur in the course of infectious, metabolic, traumatic, toxic, and other diseases (Table **[1](#T1){ref-type="table"}**) \[[@r19]\]. Patients with cognitive deficits who do not meet the criteria for dementia are considered to have Mild Cognitive Impairment (MCI), an objective cognitive impairment with preserved function (Table **[2](#T2){ref-type="table"}**) \[[@r20]\].

Alzheimer's disease is clinically manifested by a progressive memory loss and impairment of other cognitive processes lasting over decades \[[@r21]\]. Major neuropathological hallmarks of the disease are the extracellular presence of beta-amyloid (Aβ) peptide, the intracellular accumulation of neurofibrillary tangles composed of hyperphosphorylated tau and the loss of cholinergic neurons in the brain \[[@r22], [@r23]\]. Tissue changes precede the onset of clinical signs by many years, and neuropathological lesions can be found in individuals who presently do not have symptoms, for they emerge many years after the initiation of the pathological processes in the brain, when neuronal and synaptic loss cannot be compensated anymore by brain plasticity \[[@r24]\]. Genetically, the disease is divided into familial cases and sporadic cases; a vast majority of them manifest as a late-onset sporadic form. Despite many years of research, a full understanding of the etiology of the sporadic form is not yet in reach \[[@r25]\]. The familial form is due to mutations in three major genes (Amyloid Precursor Protein (APP) gene, presenilin1 (PSEN1) gene and presenilin 2 (PSEN2) gene) and is associated with a series of pathophysiological changes over decades in Cerebrospinal Fluid (CSF) biochemical markers, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment \[[@r26]\].

Mild cognitive impairment is a relatively new concept with the definition published by the American Neurological Academy in 2001 \[[@r27]\], and updated in 2018 \[[@r28]\]. Initially, the term defined a transitional state between cognitive changes accompanying the physiological aging process, and dementia, whereas currently, it is considered an independent clinical entity \[[@r6], [@r29]\]. As a group of evident and objective cognitive deficits in patients without dementia diagnosis, MCI is divided into 4 subtypes, of which, the amnestic one could constitute a prodromal stage of AD \[[@r30]\]. MCI is, however, much more heterogeneous than preclinical AD; patients report memory and/or other cognitive function deficits that do not impact the execution of basic everyday activities, but significantly decrease the quality of life through deterioration of complex daily activities \[[@r28], [@r30]\]. Current knowledge of MCI is limited. Empirical verification is needed specifically for identification of cases that convert into dementia, with cumulative dementia incidence being 14.9% in individuals with MCI older than 65 followed for 2 years, and those with relatively stable - or even improving - cognitive deficits, with reports varying between 14.4% and 55.6% of patients reverting to normal \[[@r28]\]. Due to the higher risk of developing dementia, early diagnosis and monitoring of all people with MCI are recommended. Such conduct forms the basis for deepening the diagnosis, and implementing therapy, and is dictated by obvious advantages to early treatment of dementia. Currently, no high-quality evidence exists to support pharmacologic treatments for MCI, but regular exercise and cognitive training are among the latest major recommendations \[[@r28]\].

1.2. Cholesterol {#sec1.2}
----------------

Early findings indicated that hypercholesterolemia - expecially high midlife total cholesterol - can be an important risk factor of neurodegenerative diseases and dementia. However, causing role of high cholesterol levels in AD or MCI has not been confirmed and findings concerning circulating cholesterol and dementia are contradictory. The factor that has been suspected of having associations with neurodegeneration is an altered metabolism of brain cholesterol. There are findings suggesting that oxysterols are one of the main factors triggering AD. Because the vast majority of circulating 24(S)-OHC origins in the brain, it is suggested that its concentrations in the CSF and/or plasma can pose peripheral neuronal degeneration markers. It remains to be determined and a challenge to establish if brain cholesterol structure and functions are altered in dementia patients.

Statins, in addition to reducing blood lipids, have potential in regulating cholesterol metabolism in the brain, and supposed role in prevention and treatment of dementia. Their antioxidant and anti-inflammatory effects seem to promote cardiovascular and cerebrovascular health, and might confer neuroprotection through other mechanisms. In spite of a notion suggesting a protective effect of statin use on cognitive decline, it may be attributable to research bias. Initiation of statin use in late life does not seem to prevent cognitive decline and dementia over the subsequent years. The current literature does not address the questions of whether mid-life or long-term statin use have beneficial effects on cognition. In its most recent clinical guideline, the American Academy of Neurology does not address statin use to prevent dementia.

While ApoE is known to be the major mechanism of cholesterol transport within the brain, its direct involvement in AD pathogenesis is unknown and remains an important topic in AD research. Available findings suggest that ApoE status needs to be considered when assessing the relationship between lipid levels and AD risk in population studies and that cholesterol transport may play an important role in the progression of AD.

Cholesterol is a compound synthesized exclusively in animal organisms. About 60% of endogenous cholesterol in humans is produced in the liver, 15% in bowels, and the remainder in the skin. Cholesterol is an important structural component of nerve cells, and the brain is the most cholesterol-rich organ, containing about 20% of the total body's cholesterol \[[@r18]\]. Brain cholesterol exists in two pools: the plasma membranes of neurons and glial cells and the myelin membranes \[[@r31]\], with the majority (70%) located in the myelin \[[@r32]\]. Cholesterol is the main constituent of cell membranes \[[@r33]\]. In many neurons, it constitutes the myelin sheath providing insulation for the conduction of nerve impulses; therefore, its loss greatly contributes to neurological problems. Cholesterol affects the functioning of brain synapses, and is crucial in production, and secretion of neurotransmitters. Cholesterol and lipid homeostasis are critical for normal brain function, including neuronal repair, membrane remodeling, and plasticity \[[@r34]\]. A link between cholesterol metabolism defects and neurodegenerative disorders is now recognized (Fig. **[1](#F1){ref-type="fig"}**) \[[@r31]\].

Classical research on cholesterol and cognition was initiated decades ago by an interesting observation by Sparks *et al*., who noticed senile plaques, resembling the ones in AD, in brains of patients with advanced Coronary Heart Disease (CHD) \[[@r35]\]. A subsequent research claimed that feeding rabbits with high cholesterol diet caused occurrences of plaques in the brain tissue \[[@r36]\]. Those initial studies sparked numerous research works on cholesterol and cognitive impairment, from searching for relationship between cholesterol and Aβ, to associating statins with AD, in both animals and humans. Findings indicated that hypercholesterolemia -- especially high midlife Total Cholesterol (TC) - increases the risk of late-life AD, and may correlate with the onset of AD pathology \[[@r37]\], suggesting that it can be an important risk factor for neurodegenerative diseases \[[@r38]\]. Some reports, mostly from retrospective epidemiological studies, mentioned lower AD prevalence among patients on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins \[[@r39]-[@r44]\].

1.3. Cholesterol, Statins, and Dementia {#sec1.3}
---------------------------------------

Statins have been widely used clinically. They comprise the first-line drug therapy for the treatment of hyperlipidemia and prevention of CHD \[[@r45]\]. In addition to reducing blood lipids, their potential in regulating cholesterol metabolism in the brain, \[[@r46]\] and the supposed role in the prevention and treatment of dementia, have been eagerly discussed \[[@r47], [@r48]\]. Their antioxidant and anti-inflammatory effects seem to promote cardiovascular and cerebrovascular health \[[@r49], [@r50]\], and might confer neuroprotection through other mechanisms, *i.e*. lipophilic statins might cross the blood-brain barrier and exert antioxidant and anti-inflammatory effects within the CNS \[[@r49], [@r51]\]. Given the potential role of dyslipidemia in the development of dementia, statins have been proposed as potential therapeutic options to inhibit or prevent the disease \[[@r52]\]. Experiments in animal and cell models of AD also suggest that statins modulate both Aβ and brain tau metabolism \[[@r53], [@r54]\]; however, little evidence currently supports a similar effect in humans \[[@r49]\].

Statins have become a cornerstone of treatment for dyslipidemia mainly due to their marked lowering of Low-Density Lipoprotein Cholesterol (LDL-C). Findings suggest that statin treatment typically reduces the relative risk of cardiovascular disease by 24-37%, regardless of age, sex, prior history of CHD, or other co-morbid conditions \[[@r55]\]. Also, evidence that more intensive lipid-lowering regimens could provide additional clinical benefits, has been found \[[@r55]\]. A recent meta-analysis of 31 studies involving a total of 3332.706 participants with 184.666 incident cases found that statin use was associated with a reduction in AD and other forms of dementia risk in both women and men \[[@r48]\]. Although statin use potentially may be able to prevent cognitive impairment \[[@r56]\], growing concerns, partly due to the conflicting results of the associations between their use and dementia, have emerged \[[@r48]\].

In the United States, nearly 30% of adults aged 40 years and older are on statin \[[@r57]\]. It is the first choice cholesterol-lowering medication for 93% of them, with increasing use \[[@r58]\]. Its widespread use highlights the importance of careful consideration of its varied effects on the body. According to Power *et al*, previously discussed protective effect of decreasing the risk of dementia and improving cognitive impairment, reported from observational studies that considered statin use at or near the time of dementia diagnosis, could be attributable to reverse causation \[[@r59]\]. Moreover, statins have also been shown to have the ability to cause reversible cognitive impairment in some patients. However, well-designed randomized controlled trials have failed to find both cognitive impairing, and the beneficial effects. Two randomized controlled trials with 26.340 participants 40 to 82 years of age, including 11.610 individuals aged 70 years or older \[[@r60]\] comparing simvastatin and pravastatin with placebo over 5 and 3.2 years, respectively, with all of the participants in both study populations of a moderate to high vascular risk, found no differences in the number of patients who developed dementia or cognitive decline between those on statins or placebo. Both the studies were at low risk of bias, and there were no differences in the number of adverse effects leading to discontinuation \[[@r61]\]. It seems that firm conclusions about whether mid-life or long-term statin use has an impact on cognitive decline and dementia remain elusive. Randomized controlled trials do not support a causal preventative effect of late-life statin use on cognitive decline or dementia \[[@r59]\]. The contradicting results may be explained by seemingly independent mechanisms that have been hypothesized for each effect.

Stronger evidence, associating cholesterol with AD causally, was brought by experimental studies demonstrating that manipulating with cholesterol levels modified the levels of APP and Aβ \[[@r62]\]. However, there are numerous doubts about this hypothesis. Some studies did not find significant differences or even suggested that cholesterol levels of AD patients were lower than controls \[[@r63], [@r64]\]. Interestingly, it was postulated that the decline in cholesterol levels might actually contribute to the development of dementia \[[@r65]\]. According to the authors, the decline was unlikely to be explained by behavioral or metabolic changes associated with MCI, and the processes underlying it may represent occurrences early in the course of the disease or may be a marker for factors underlying both physical and cognitive decline in old age. As concluded, research on associations between cholesterol levels and risk of dementia should take into account the physical health status as it may have a modifying role \[[@r65]\]. In this instance, hypocholesterolemia might be associated with frailty, poor general health \[[@r66]\], inflammatory markers and poor nutritional status \[[@r67]\]. Finally, the latest longitudinal study demonstrated that higher visit-to-visit variability in TC, rather than mean TC, is associated with an increased risk of dementia and AD in the general population, which infers that variability in cholesterol level may be a novel predictor of upcoming dementia \[[@r68]\].

Also, prospective studies on statins and AD have not fully confirmed such relationships \[[@r69]-[@r71]\]. Clinical statin manipulations aimed at lowering cholesterol levels in order to prevent and cure neurodegeneration proved unsuccessful \[[@r72]\]. In addition, it has been postulated that the beneficial effect of statins could be a result of their anti-inflammatory rather than the cholesterol-lowering action \[[@r73]\]. Even experimental data is open to various interpretations as cholesterol level modifications typically impact many proteins, not limited to APP and beta-amyloid \[[@r74]\].

Summary of the key findings concerning statin effect on cognition suggests that initiation of statin use in late life does not seem to prevent cognitive decline and dementia over the subsequent years. The current literature does not address the questions of whether mid-life or long-term statin use has beneficial effects on cognition. Many findings indicate a protective effect of statin use on cognitive decline, but it may be attributable to research bias. Future observational work must incorporate study designs that minimize the potential for bias, especially that, which is due to confounding and reverse causation \[[@r59]\]. In its most recent clinical guideline, the American Academy of Neurology does not address statin use to prevent dementia \[[@r75]\]. In view of the current knowledge, understanding its complex effects, together with the ability to identify patients at risk for or already experiencing cognitive impairment from statin use, as well as those who could potentially decrease their risk of dementia with statins seems crucial for health care providers \[[@r57]\].

Circulating cholesterol cannot penetrate the Blood-Brain Barrier (BBB) \[[@r18]\], although - interestingly - it has been shown that in a transgenic mouse model, a small amount of cholesterol from the periphery can enter the brain through the BBB and could play a role in hypercholesterolemia and the CSF levels of brain cholesterol \[[@r76]\]. Generally, the above premises do not confirm the causal role of high cholesterol levels in AD or MCI \[[@r38]\]. Molecular mechanisms constituting neurodegeneration are still not clear and currently, we are not in disposal of any certain biomarkers for early diagnosis \[[@r77]\]. Over the years, along with oxidative stress and neuroinflammation, the factor that has been suspected of having associations with neurodegeneration is an altered metabolism of brain cholesterol \[[@r78]\]. There are studies suggesting that oxidized derivatives of cholesterol - oxysterols (OHC) - are one of the main factors triggering AD \[[@r79], [@r80]\]. OHC are biologically active cholesterol metabolites that may be formed enzymatically or by autoxidative mechanisms \[[@r81]\]. OHC, such as 27-OHC, 24S-hydroxycholesterol (24(S)-OHC), 7α--OHC i 7β-OHC are not only able to penetrate the BBB but also have cytotoxic and proapoptotic characteristics. Of these, 24SOHC is the most abundant oxysterol in the brain, and potentially predominantly involved in neurodegenerative disorder pathogenesis \[[@r82]\].

1.4. 24(S)-Hydroxycholesterol {#sec1.4}
-----------------------------

Defects in brain cholesterol metabolism were described in certain neurodegenerative diseases such as Sclerosis Multiplex and Huntington's Disease \[[@r83]\]. Because BBB effectively blocks cholesterol transport from circulation to cerebrospinal fluid, *de novo* synthesis is responsible for almost the entire cholesterol present in the brain \[[@r84]\]. The conversion of cholesterol to 24SOHC is catalyzed by cholesterol 24-hydroxylase (CYP46A1), which is predominantly expressed in the brain \[[@r32]\]. In the absence of neurodegeneration, concentrations of 24-OHC are relatively stable between the third and seventh decades of life. Beyond the six-decade of life, plasma levels of 24-OHC begin to decline with age \[[@r85]\] which parallels the decline in total brain volume with age \[[@r86]\]. Because the vast majority of circulating 24(S)-OHC originate in the brain, it is suggested that their concentrations in the CSF and/or plasma can pose peripheral neuronal degeneration markers of neurodegenerative diseases \[[@r87]\]. 24(S)-OHC is therefore an interesting, but a possible marker of neurodegeneration in general, probably also useful for AD \[[@r88]\].

Plasma concentrations of 24(S)-OHC depend on the balance between their production in the brain and elimination from the liver, and are associated with the number of metabolically active neurons. They are modified by cholesterol turnover factors, plasma lipoprotein metabolism, genetic factors, and lifestyle \[[@r89]\]. It has been postulated that plasma levels of 24(S)-OHC can potentially be used as an early biochemical marker of altered cholesterol homeostasis in the Central Nervous System (CNS) \[[@r90]\]. Following studies brought conflicting results, finding normal \[[@r87]\] or lowered \[[@r91]-[@r93]\] levels of 24(S)-OHC in dementia compared to controls. Zuliani *et al*. suggest that plasma levels of 24(S)-hydroxycholesterol can be elevated in early phases of AD due to systemic inflammation \[[@r94]\]. Those findings support the hypothesis that higher levels of 24(S)-OHC in early AD occur when neurodegeneration coefficient is higher than normal, but the extent of neuron loss and brain atrophy remains relatively small, and these levels decrease with the disease progression, when neuronal damage provides higher levels of cholesterol to be converted into 24S-OHC \[[@r90], [@r91]\]. The exact mechanisms leading to an increase in plasma 24(S)-OHC levels in early stages of AD are not known. It is possible that cholesterol turnover is elevated due to neuronal degradation \[[@r94]\]. There are evidence that lowered plasma 24(S)-OHC levels in advanced stages of dementia are associated with the loss of metabolically active nerve cells and the atrophy degree of cell membranes. Blood-brain barrier dysfunctions, presence of inflammation, or elevated cholesterol turnover can all counteract this tendency, resulting in elevation, or, sometimes, alteration of those levels \[[@r87]\].

Unlike plasma 24S-OHC concentrations, the CSF levels seem to be more sensitive to modifications in the brain and not affected by hepatic clearance \[[@r95]\]. Therefore, they may be better markers for neurodegenerative diseases and disruptions of the BBB \[[@r96], [@r97]\]. It has been demonstrated that CSF 24S-OHC levels are significantly higher in the early stages of AD, and decrease with its progression, suggesting increased cholesterol turnover in the CNS during degeneration \[[@r87], [@r98]\], and reflecting the loss of cells expressing cholesterol 24-hydroxylase as the disease advances \[[@r99]\].

In spite of existing evidence on associations of oxysterols with neurodegenerative diseases, very few studies have focused on the assessment of the relationship between oxysterols and MCI, providing promising preliminary results suggesting that elevated levels of 24(S)-hydroxycholesterol \[[@r97]\] or 27-hydroxycholesterol \[[@r38]\] in CSF can be a sensitive marker of neurodegeneration in patients with MCI. The latest meta-analysis \[[@r100]\] points out that cholesterol, 24-OHC, and 27-OHC levels in CSF are elevated in MCI patients compared to controls, and that there is a significant dysfunction of cholesterol metabolism in the CSF of AD subjects. This indicates that in addition to the available biomarkers in the CSF, 24(S)-OHC, 27-OHC, and cholesterol appear to be sensitive biomarkers for the evaluation of MCI and AD. Authors postulate a mechanism in which cholesterol homeostasis is disturbed in preclinical AD, whereas metabolite dysregulation occurs throughout the disease process; changes in cholesterol and its metabolites might serve as additional biomarkers for the diagnosis and screening of AD. Most importantly, they might help identify a sub-group of AD patients with lipid metabolism dysregulation who might have different clinical presentations and clinical courses.

1.5. Cholesterol, ApoE and AD {#sec1.5}
-----------------------------

Cholesterol's role in AD remained largely ignored until the discovery of Apolipoprotein E (ApoE) as the primary genetic risk factor for sporadic AD (\> 95% cases) \[[@r101]\]. The human ApoE gene exists as three different alleles, ε2, ε3, and ε4 \[[@r102]\], of which homozygous ApoE4 carriers are approximately 15-times more likely to develop the disease. With 25% of the population being ApoE4 carriers, understanding the role of this allele in AD pathogenesis and pathophysiology is crucial \[[@r103]\]. ApoE plays a pivotal role in lipoprotein metabolism in both the brain and periphery. The situation in the brain and in the periphery differs significantly; while CNS lipids are necessary for normal function, peripherial lipids are associated with risk of atherosclerotic lesions \[[@r104]\]. While ApoE is known to be the major mechanism of cholesterol transport within the brain, its direct involvement in AD pathogenesis is unknown and remains an important topic in AD research \[[@r88]\]. The association between ApoE, cholesterol and AD has been reviewed by several researchers \[[@r95], [@r105]-[@r112]\]. Among several mechanisms that have been proposed to explain that link, interesting hypotheses of impaired delivery of cholesterol from astrocytes to neurons, such that ApoE4 performs this activity less efficiently \[[@r113]\], and that of the three isoforms, ApoE4 is responsible for increasing cholesterol in the brain to a greater extent than ApoE3 \[[@r114]\], have been presented. The latter is supported by clinical findings and suggests that it could be a potential therapeutic target for disease prevention \[[@r115]\]. Converging evidence indicates a role of the relationships between ongoing deterioration of brain lipid homeostasis and vascular changes as risk factors for cardiovascular disease, such as high midlife plasma cholesterol, diabetes, stroke, obesity and hypertension, in the AD pathophysiology \[[@r115]\].

In spite of decades of intensive research, molecular mechanisms of ApoE4 promoting Alzheimer\'s disease, as well as processes mediated by this lipoprotein, which could be attractive pharmaceutical targets for the prevention and treatment of AD, are still unknown \[[@r103], [@r116]\]. Nonetheless, available findings suggest that ApoE status needs to be considered when assessing the relationship between lipid levels and AD risk in population studies \[[@r117]\] and that cholesterol transport may play an important role in the progression of AD \[[@r103]\].

CONCLUSION
==========

If the expected lifespan elongation pace in the civilized countries maintains, the majority of newborns after the year 2000 will celebrate their 100 birthday \[[@r118]\]. The key question is: will this growth in life expectancy be accompanied by cognitive wellbeing or impairment? This debate, fueling decades of research on cholesterol in the context of cognitive performance, still remains open. Despite the plethora of studies on the relationships between both circulating cholesterol as a risk factor for cognitive decline, and brain cholesterol metabolism and dementia, so far no single trusted indicator of an early cognitive deterioration has been identified. The causal role of high cholesterol levels in AD or MCI has not been confirmed. It remains to be determined and a challenge to establish if brain cholesterol structure and functions are altered in dementia patients \[[@r74]\]. Future research aimed at identifying the mechanisms that underlie the effects of its metabolism and transport not only may provide important insight into the causes and interdependencies of cognitive impairment and dementia, but also inspire novel strategies for treating and preventing these disorders. However, the current state of knowledge makes the use of cholesterol markers of cognitive decline in clinical practice impossible \[[@r119]\].
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###### 

Dementia types and characteristics.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **DEMENTIA**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Term describing a collection of symptoms caused by disorders affecting the brain with common characteristics of the loss of intellectual and cognitive functions. It refers to a clinical syndrome characterized by progressive cognitive decline that interferes with the ability to function independently. Symptoms of dementia are gradual, persistent and progressive. The clinical presentation of the syndrome varies greatly among individuals causing impairments such as memory loss, communication and language impairments, agnosia, apraxia and impaired executive function.**                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------
  60 - 80% of cases progressive memory loss and impairment of other cognitive processes visual/spatial and language impairment lasting over decades                                                                                                                                                                                                                                                                                                                                                                                                                                               20% of cases abrupt onset motor dysfunction, aphasia, mood/ behavioral changes causal/temporal relationship between a vascular event and cognitive impairment   15% of cases visual hallucinations delusions, falls, fluctuating memory problems with movement and changes in mental abilities   8 - 10% of cases personality and behavior changes difficulties with language executive dysfunction disinhibition impulsivity   1% of cases caused by potentially reversible factors may occur in the course of infectious, metabolic, traumatic, toxic, and other diseases

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Mild cognitive impairment types.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **MILD COGNITIVE IMPAIRMENT**\                                                                                                                                                                                                                                                                                                                                                                                                    
  **Term describing a group of evident and objective cognitive deficits in patients without dementia diagnosis and with preserved function. MCI is classified into two subtypes: amnestic and non-amnestic, based on the involvement of memory, and single domain or multiple domain, based on involvement of the number of cognitive domains affected.**                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ----------------------------------- --------------------------------------
  Only memory affected                                                                                                                                                                                                                                                                                                                                      Single non-memory domain affected   Memory and other domains affected   Multiple non-memory domains affected

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
